Bioventus (BVS) Financials: Revenue & Earnings

BVS price $14.65 +0.23 +1.63%

Ticker
BVS
Price
$14.65
Change
+0.23 +1.63%
Market cap ?
$1.00B
P/E ?
17.95
Forward P/E ?
18.82
Dividend yield ?
0.00%
Beta ?
0.64
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
56
Value
55
Quality
59
Growth
54

Stocklytics score rationale: value 55, quality 59, growth 54.

Financials

2016201720182019202020212022202320242025
274500000292059000319177000340141000321161000430898000512117000512345000573280000568087000

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to…

Fair value

BVS fair value $35.37. Price $14.65. Price is 59% below fair value.

Below fair value, and cheaper than usual. A larger discount than on 72% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 94.29M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 68.31M. Net debt 260.11M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare BVS

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-03—0.15—149.51M
2026-08-050.220.22153.21M155.44M
2026-05-060.150.09132.09M129.91M
2026-03-050.240.22157.90M154.95M
2025-11-040.150.21138.65M155.70M
2025-08-060.210.22147.66M138.78M
2025-05-060.080.06123.88M145.85M
2025-03-110.150.08153.64M124.50M
2024-11-050.060.06138.96M144.83M
2024-08-060.190.07151.22M137.59M
2024-05-070.07-0.05129.46M118.38M
2024-03-120.070.06135.42M123.96M
2023-11-070.050.06120.79M123.96M
2023-08-080.140.03137.07M129.23M
2023-05-16-0.26-0.11119.06M116.58M
2023-03-31-0.060.05125.83M132.70M
2022-11-080.050.13137.07M141.59M
2022-08-110.100.14140.33M138.33M
2022-05-100.040.05117.29M117.69M
2022-03-100.260.20130.41M130.23M
2021-11-090.250.13108.89M104.95M
2021-08-100.160.10109.82M109.82M
2021-05-12-0.02-0.0181.78M478.40M
2021-03-252.320.2398.59M—
2021-02-120.15—85.91M—
2020-06-30-0.10—58.02M—
2020-03-310.19—78.64M—
2019-12-311.15—97.55M—
2019-09-280.07—82.24M—
2019-06-29-0.05—80.17M—
2019-03-29-0.05—80.17M—
2016-03-31-0.11—65.40M—
2015-03-31-0.37—53.36M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-03Bartholdson John A.Buy25.15K——
2026-06-03SUTTER MARTIN PBuy25.15K——
2026-06-03STALNECKER SUSAN MBuy25.15K——
2026-06-03NOHRA GUY PBuy25.15K——
2026-06-03NEELS GUIDO JBuy25.15K——
2026-06-03McMurry-Heath MichelleBuy25.15K——
2026-06-03Ladone Mary KayBuy25.15K——
2026-06-03HAWKINS WILLIAM ABuy30.99K——
2026-06-03Cowdy Philip G.Buy25.15K——
2026-06-03Beyer PatBuy25.15K——
2026-06-02Bartholdson John A.Buy32.28K——
2026-06-02Bartholdson John A.Sell32.28K——
2026-06-02SUTTER MARTIN PBuy32.28K——
2026-06-02SUTTER MARTIN PSell32.28K——
2026-06-02STALNECKER SUSAN MBuy32.28K——
2026-06-02STALNECKER SUSAN MSell32.28K——
2026-06-02NOHRA GUY PBuy32.28K——
2026-06-02NOHRA GUY PSell32.28K——
2026-06-02NEELS GUIDO JBuy32.28K——
2026-06-02NEELS GUIDO JSell32.28K——
2026-06-02McMurry-Heath MichelleBuy32.28K——
2026-06-02McMurry-Heath MichelleSell32.28K——
2026-06-02Ladone Mary KayBuy32.28K——
2026-06-02Ladone Mary KaySell32.28K——
2026-06-02HAWKINS WILLIAM ABuy39.79K——
2026-06-02HAWKINS WILLIAM ASell39.79K——
2026-06-02Cowdy Philip G.Buy32.28K——
2026-06-02Cowdy Philip G.Sell32.28K——
2026-06-02Beyer PatBuy32.28K——
2026-06-02Beyer PatSell32.28K——
2026-04-10Singleton Mark LeonardBuy13.00K——
2026-04-10Singleton Mark LeonardSell5.65K$9.0651.17K
2026-04-10Singleton Mark LeonardSell13.00K——
2026-04-10CHURCH KATRINA JBuy4.30K——
2026-04-10CHURCH KATRINA JSell1.87K$9.0616.92K
2026-04-10CHURCH KATRINA JSell4.30K——
2026-04-10D'Adamio AnthonyBuy9.93K——
2026-04-10D'Adamio AnthonySell4.31K$9.0639.07K
2026-04-10D'Adamio AnthonySell9.93K——
2026-03-20Singleton Mark LeonardBuy18.62K——
2026-03-20Singleton Mark LeonardSell8.09K$8.6469.91K
2026-03-20Singleton Mark LeonardSell18.62K——
2026-03-13Singleton Mark LeonardBuy13.50K——
2026-03-13Singleton Mark LeonardSell5.87K$8.6250.56K
2026-03-13Singleton Mark LeonardBuy116.00K$8.62999.92K
2026-03-13Singleton Mark LeonardBuy104.00K——
2026-03-13Singleton Mark LeonardSell13.50K——
2026-03-13CHURCH KATRINA JBuy3.50K——
2026-03-13CHURCH KATRINA JSell1.52K$8.6213.11K
2026-03-13CHURCH KATRINA JBuy3.46K——
2026-03-13CHURCH KATRINA JSell1.50K$8.6212.94K
2026-03-13CHURCH KATRINA JBuy27.00K$8.62232.74K
2026-03-13CHURCH KATRINA JBuy24.00K——
2026-03-13CHURCH KATRINA JSell3.50K——
2026-03-13CHURCH KATRINA JSell3.46K——
2026-03-13D'Adamio AnthonyBuy8.75K——
2026-03-13D'Adamio AnthonySell3.80K$8.6232.77K
2026-03-13D'Adamio AnthonyBuy8.89K——
2026-03-13D'Adamio AnthonySell3.86K$8.6233.28K
2026-03-13D'Adamio AnthonyBuy92.00K$8.62793.04K
2026-03-13D'Adamio AnthonyBuy83.00K——
2026-03-13D'Adamio AnthonySell8.75K——
2026-03-13D'Adamio AnthonySell8.89K——
2026-03-13Claypoole Robert EBuy309.00K$8.622.66M
2026-03-13Claypoole Robert EBuy278.00K——
2026-03-13Claypoole Robert EBuy33.50K——
2026-03-13Claypoole Robert ESell14.55K$8.62125.45K
2026-03-13Claypoole Robert ESell33.50K——
2026-03-11McMurry-Heath MichelleSell12.00K$8.79105.44K
2026-02-15Singleton Mark LeonardBuy20.15K——
2026-02-15Singleton Mark LeonardSell9.43K$8.2777.98K
2026-02-15Singleton Mark LeonardSell20.15K——
2026-02-15CHURCH KATRINA JBuy4.38K——
2026-02-15CHURCH KATRINA JSell2.13K$8.2717.64K
2026-02-15CHURCH KATRINA JSell4.38K——
2026-02-15D'Adamio AnthonyBuy12.98K——
2026-02-15D'Adamio AnthonySell6.33K$8.2752.32K
2026-02-15D'Adamio AnthonySell12.98K——
2026-01-09Claypoole Robert ESell93.75K——
2026-01-09Claypoole Robert EBuy93.75K——
2026-01-09Claypoole Robert ESell41.72K$8.03334.99K
2025-12-04NOHRA GUY PSell10.00K$7.5775.66K
2025-11-14Dhankhar AjayOther0——
2025-11-07McMurry-Heath MichelleSell17.70K$7.42131.25K
2025-06-06Bartholdson John A.Buy7.58K——
2025-06-06Bartholdson John A.Sell7.58K——
2025-06-03Bartholdson John A.Buy32.28K——
2025-06-03SUTTER MARTIN PBuy32.28K——
2025-06-03STALNECKER SUSAN MBuy32.28K——
2025-06-03NOHRA GUY PBuy32.28K——
2025-06-03NEELS GUIDO JBuy32.28K——
2025-06-03McMurry-Heath MichelleBuy32.28K——
2025-06-03Ladone Mary KayBuy32.28K——
2025-06-03HAWKINS WILLIAM ABuy39.79K——
2025-06-03Cowdy Philip G.Buy32.28K——
2025-06-03Beyer PatBuy32.28K——
2025-06-02Bartholdson John A.Buy26.49K——
2025-06-02Bartholdson John A.Sell26.49K——
2025-06-02SUTTER MARTIN PBuy26.49K——
2025-06-02SUTTER MARTIN PSell26.49K——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 161, holders +2 vs prior quarter. Ownership 79.92%.

HolderSharesChangeChange %Value
ESSEX WOODLANDS MANAGEMENT, INC.13.02M00.00%122.92M
JUNIPER INVESTMENT COMPANY, LLC6.94M00.00%65.51M
NANTAHALA CAPITAL MANAGEMENT, LLC6.00M-122.12K-1.99%56.64M
BLACKROCK, INC.3.44M302.37K+9.65%32.44M
ROYCE & ASSOCIATES LP1.83M291.93K+18.94%17.31M
VANGUARD CAPITAL MANAGEMENT LLC1.75M36.97K+2.16%16.54M
GEODE CAPITAL MANAGEMENT, LLC1.37M197.47K+16.90%12.89M
AMERICAN CENTURY COMPANIES INC1.35M733.61K+118.36%12.78M
DIMENSIONAL FUND ADVISORS LP1.13M255.33K+29.24%10.65M
STATE STREET CORP1.10M116.51K+11.79%10.43M
VANGUARD PORTFOLIO MANAGEMENT LLC1.04M69.79K+7.17%9.84M
HILLSDALE INVESTMENT MANAGEMENT INC.907.74K236.60K+35.25%8.57M
ENGINE CAPITAL MANAGEMENT, LP900.56K585.54K+185.88%8.50M
WELLINGTON MANAGEMENT GROUP LLP748.36K594.22K+385.50%7.06M
RENAISSANCE TECHNOLOGIES LLC736.00K246.54K+50.37%6.95M
OBERWEIS ASSET MANAGEMENT INC/709.71K81.60K+12.99%6.70M
GOLDMAN SACHS GROUP INC652.37K178.98K+37.81%6.16M
KENNEDY CAPITAL MANAGEMENT LLC466.56K-8.41K-1.77%4.40M
FMR LLC452.85K56.62K+14.29%4.27M
NORTHERN TRUST CORP443.82K81.00K+22.33%4.19M
PRUDENTIAL FINANCIAL INC394.52K200.72K+103.57%3.72M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC391.86K17.92K+4.79%3.70M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.391.86K391.86KNew3.70M
TOCQUEVILLE ASSET MANAGEMENT L.P.369.67K24.67K+7.15%3.49M
ACADIAN ASSET MANAGEMENT LLC337.00K3.88K+1.17%3.18M

Earnings and financials

Bioventus Inc. (BVS) trades at $14.65, with a market cap of $1.00B and a trailing P/E of 17.95. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
274500000292059000319177000340141000321161000430898000512117000512345000573280000568087000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Bioventus (BVS) Financials: Revenue & Earnings

BVS$14.65+0.23 +1.63%

$1.00B

Market Cap

17.95

P/E

18.82

Forward P/E

56

Score

Price History